DataMabs

DataMabs is a biotechnology company specializing in the computational design and optimization of monoclonal antibodies. Founded as a spin-out from the University of Oxford, the company utilizes advanced machine learning and structural bioinformatics to predict antibody properties and enhance developability. In January 2021, DataMabs was acquired by Exscientia to serve as the core of its new biologics discovery arm. This acquisition enabled Exscientia to expand its AI-driven drug discovery platform beyond small molecules into the realm of complex biologics. The company's technology focuses on reducing the time and risk associated with traditional antibody engineering.